Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease.

[1]  R. Bonow,et al.  Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! , 2012, Journal of the American College of Cardiology.

[2]  Marc P. Bonaca,et al.  Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. , 2012, Journal of the American College of Cardiology.

[3]  F. Apple,et al.  N-terminal and C-terminal fragments of IGFBP-4 as novel biomarkers for short-term risk assessment of major adverse cardiac events in patients presenting with ischemia. , 2012, Clinical biochemistry.

[4]  I. Knezevic,et al.  A Novel Cardiomyocyte-enriched MicroRNA, miR-378, Targets Insulin-like Growth Factor 1 Receptor , 2012, The Journal of Biological Chemistry.

[5]  S. Chakravarthi,et al.  Insulin Like Growth Factor-1 (IGF-1) Causes Overproduction of IL-8, an Angiogenic Cytokine and Stimulates Neovascularization in Isoproterenol-Induced Myocardial Infarction in Rats , 2011, International journal of molecular sciences.

[6]  A. Jaffe,et al.  Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease: use of a new monoclonal antibody-based assay. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[7]  P. Porela,et al.  Free vs total pregnancy-associated plasma protein A (PAPP-A) as a predictor of 1-year outcome in patients presenting with non-ST-elevation acute coronary syndrome. , 2010, Clinical chemistry.

[8]  A. Jaffe,et al.  PAPP-A as a marker of increased long-term risk in patients with chest pain. , 2009, Clinical biochemistry.

[9]  A. Jaffe,et al.  Analytic and clinical utility of a next-generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. , 2009, Clinical chemistry.

[10]  J. Ambrose.  In search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention? , 2008, Journal of the American College of Cardiology.

[11]  R. Schwartz,et al.  Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. , 2006, Journal of the American College of Cardiology.

[12]  F. Crea,et al.  Pregnancy-associated plasma protein-A and acute coronary syndromes: cause or consequence? , 2005, Journal of the American College of Cardiology.

[13]  F. Crea,et al.  Pregnancy associated plasma protein-A and coronary atherosclerosis: marker, friend, or foe? , 2005, European heart journal.

[14]  P. Libby,et al.  Pathophysiology of Coronary Artery Disease , 2005, Circulation.

[15]  F. Crea,et al.  Insulin-Like Growth Factor-1 as a Vascular Protective Factor , 2004, Circulation.

[16]  B. Lindahl,et al.  Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. , 2004, American heart journal.

[17]  P. Porela,et al.  Circulating Pregnancy-Associated Plasma Protein A Predicts Outcome in Patients With Acute Coronary Syndrome but No Troponin I Elevation , 2003, Circulation.

[18]  Qunhua Huang,et al.  Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression. , 2002, Circulation research.

[19]  K. Bailey,et al.  Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. , 2001, The New England journal of medicine.

[20]  L. Giudice,et al.  Pregnancy‐associated plasma protein‐A (PAPP‐A) cleaves insulin‐like growth factor binding protein (IGFBP)‐5 independent of IGF: implications for the mechanism of IGFBP‐4 proteolysis by PAPP‐A , 2001, FEBS letters.

[21]  David O. Williams,et al.  ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .

[22]  A. Bayés‐Genís,et al.  The insulin-like growth factor axis: A review of atherosclerosis and restenosis. , 2000, Circulation research.

[23]  P. Thompson,et al.  ACSM's Guidelines for Exercise Testing and Prescription , 1995 .

[24]  J. Reiber,et al.  Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA. , 1992, European heart journal.

[25]  W. Santamore,et al.  Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? , 1988, Circulation.

[26]  T. Ryan.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.

[27]  V. Fuster,et al.  Angiographic progression of coronary artery disease and the development of myocardial infarction. , 1988, Journal of the American College of Cardiology.

[28]  C. Terkelsen,et al.  Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myocardial infarction patients and potential significance of concomitant heparin administration. , 2009, The American journal of cardiology.

[29]  Kim Pettersson,et al.  Molecular distinction of circulating pregnancy-associated plasma protein A in myocardial infarction and pregnancy. , 2005, Clinical chemistry.